Account

Search results for: vpag

VPAG for manufacturers: boom or gloom for UK launc...

We discuss the 2024 VPAG agreement, how it differs from the previous VPAS and whether this will impa...

Read more
VPAS is dead, long live VPAG: the impact of the UK...

Webinar: Discussions on the new Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (...

Read more
World EPA Congress 2024: Implications of indicatio...

The study explores the complexities of pricing and reimbursement for multi-indication products in th...

Read more
Is the attractiveness of launch in the UK changing...

This expert article focusses on the new proportionate approach, and the international recognition pr...

Read more
What are the 5 Pricing & Market Access trends...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more
Reflecting on the Pricing & Market Access tre...

Back in January this year, we summarised the key trends our market access experts believed would dom...

Read more
New rebate percentages in the Statutory Scheme are...

The statutory scheme has been updated with new percentages for 2024-2026, and has received backlash ...

Read more
Landmark deal reached on UK voluntary rebate schem...

Government, NHS, and Pharma Industry Unveil Successor to Voluntary Scheme for Branded Medicines Pric...

Read more
ABPI sets out new proposals in VPAG

ABPI announces new VPAG, which focuses on restoring the commercially competitive environment for lif...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch